Disseminated intravascular coagulation diagnostic study of choice
Disseminated intravascular coagulation Microchapters |
Differentiating Disseminated intravascular coagulation from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Disseminated intravascular coagulation diagnostic study of choice On the Web |
American Roentgen Ray Society Images of Disseminated intravascular coagulation diagnostic study of choice |
FDA on Disseminated intravascular coagulation diagnostic study of choice |
CDC on Disseminated intravascular coagulation diagnostic study of choice |
Disseminated intravascular coagulation diagnostic study of choice in the news |
Blogs on Disseminated intravascular coagulation diagnostic study of choice |
Directions to Hospitals Treating Disseminated intravascular coagulation |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3]
Overview
There is no single diagnostic study of choice for DIC, though DIC may be diagnosed based on the diagnostic criteria established by Japanese Society on Thrombosis and Hemostasis.
Diagnostic Study of Choice
Study of choice
There is no single diagnostic study of choice for the diagnosis of disseminated intravascular coagulation. DIC is a clinical as well as a laboratory diagnosis.
Name of Diagnostic Criteria
There is no single diagnostic study of choice for DIC, though DIC may be diagnosed based on the diagnostic criteria established by Japanese Society on Thrombosis and Hemostasis.[1]
JSTH’s DIC diagnostic criteria[1]
Classification of type | Basic | Hematopoietic disorder | Infectious | ||||
Global coagulation tests | Platelet count (×103/μl) | >120 | 0 p | >120 | 0 p | ||
80 < − ≤ 120 | 1 p | 80 < − ≤ 120 | 1 p | ||||
50 < − ≤ 80 | 2 p | 50 < − ≤ 80 | 2 p | ||||
≤50 | 3 p | ≤50 | 3 p | ||||
≥30% decrease w/in 24 h (*1) | +1 p | ≥30% decrease w/in 24 h (*1) | +1 p | ||||
FDP
(μg/ml) |
<10 | 0 p | <10 | 0 p | <10 | 0 p | |
10 ≤ − < 20 | 1 p | 10 ≤ − < 20 | 1 p | 10 ≤ − < 20 | 1 p | ||
20 ≤ − < 40 | 2 p | 20 ≤ − < 40 | 2 p | 20 ≤ − < 40 | 2 p | ||
≥40 | 3 p | ≥40 | 3 p | ≥40 | 3 p | ||
Fibrinogen
(mg/dl) |
>150 | 0 p | >150 | 0 p | |||
100 < − ≤ 150 | 1 p | 100 < − ≤ 150 | 1 p | ||||
≤100 | 2 p | ≤100 | 2 p | ||||
Prothrombin time ratio | <1.25 | 0 p | <1.25 | 0 p | <1.25 | 0 p | |
1.25 ≤ − < 1.67 | 1 p | 1.25 ≤ − < 1.67 | 1 p | 1.25 ≤ − < 1.67 | 1 p | ||
≥1.67 | 2 p | ≥1.67 | 2 p | ≥1.67 | 2 p | ||
Hemostatic molecular markers | Antithrombin
(%) |
>70 | 0 p | >70 | 0 p | >70 | 0 p |
≤70 | 1 p | ≤70 | 1 p | ≤70 | 1 p | ||
TAT, SF or F1+2 | <2-fold of normal upper limit | 0 p | <2-fold of normal upper limit | 0 p | <2-fold of normal upper limit | 0 p | |
≥2-fold of normal upper limit | 1 p | ≥2-fold of normal upper limit | 1 p | ≥2-fold of normal upper limit | 1 p | ||
Liver failure
(*2) |
No | 0 p | No | 0 p | No | 0 p | |
Yes | −3 p | Yes | −3 p | Yes | −3 p | ||
DIC diagnosis | ≥6 p | ≥4 p | ≥5 p |
References
- ↑ 1.0 1.1 Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, Madoiwa S, Asakura H (2017). "The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis". Thromb J. 15: 17. doi:10.1186/s12959-017-0142-4. PMC 5496332. PMID 28680365.